Drug intelligence / Profile preview

trastuzumab + pyrotinib + dalpiciclib + fulvestrant

Development stage: Unknown
Lead developer: Fudan University Shanghai Cancer Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intramuscular

Overview

This combination therapeutic regimen is being evaluated in the T-sunflower Phase II clinical trial led by Fudan University for the treatment of ER+/HER2+ advanced breast cancer. The regimen integrates multiple targeted approaches: trastuzumab, a monoclonal antibody that binds to the extracellular domain of HER2; pyrotinib, a small molecule tyrosine kinase inhibitor targeting HER2 and EGFR; dalpiciclib, a selective inhibitor of CDK4 and CDK6; and fulvestrant, an estrogen receptor antagonist. This multi-pronged strategy aims to simultaneously inhibit the HER2 signaling pathway, block cell cycle progression, and suppress hormone-driven growth to overcome resistance and improve clinical outcomes in patients with hormone receptor-positive, HER2-positive metastatic breast cancer.

Other names: trastuzumab-Fudan University-breast cancer

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)ESR1 (ERα)CDK6 (Cyclin-dependent kinase 6)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ESR2 (ERβ)CDK4 (Cyclin-dependent kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on trastuzumab + pyrotinib + dalpiciclib + fulvestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab + pyrotinib + dalpiciclib + fulvestrant.

Explore the full profile